Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Here’s Hinde Group’s Updates on Becton, Dickinson and Company (BDX)

AI-generated analysis

📈 Hinde Group's first-quarter 2026 portfolio delivered a gross return of 3.80% and net return of 3.41%, outperforming the S&P 500's -4.33% return.

⚔️ Market volatility in Q1 2026 was driven by the "SaaS-pocalypse" and military actions against Iran, creating ongoing uncertainty for global financial markets.

🏥 Becton, Dickinson and Company (BDX) is a leading medical technology firm that manufactures supplies, devices, and diagnostic products used by hospitals and doctors.

💰 On May 28, 2026, BDX closed at $148.41 per share with a market capitalization of $40.89 billion and a 52-week gain of 9.42%.

🔄 On February 9, 2026, BD completed a Reverse Morris Trust transaction spinning off its Biosciences & Diagnostics Solutions business to Waters Corporation.

💵 As part of the spin-off, BDX shareholders received $4 billion in cash and 0.135 shares of Waters stock for each BDX share held.

🌍 Approximately 60% of BD's $18.5 billion revenue comes from the U.S., while around a quarter originates from Europe.

🏥 Ninety percent of hospital patients encounter at least one of the more than 45 billion medical products manufactured by BD annually.

📉 BDX is classified as a special situation investment that Hinde Group initiated in July 2025.

📊 At the end of Q1 2026, 48 hedge fund portfolios held BDX, an increase from 45 portfolios in the previous quarter.

📈 BDX reported revenue of $4.7 billion for the second quarter of fiscal 2026, representing a 2.6% year-over-year increase on a FXN basis.

🤖 Hinde Group believes certain AI stocks offer greater upside potential and carry less downside risk compared to BDX.

📉 BDX is not included in Hinde Group's list of the 40 Most Popular Stocks Among Hedge Funds heading into 2026.

🔗 Readers are directed to download the full Q1 2026 investor letter for more details on the firm's top five holdings and best picks.

Bullish Signals
  • Hinde Group initiated its position in Becton, Dickinson and Company (BDX) in July 2025, signaling confidence in the stock's long-term potential.
  • The company completed a significant Reverse Morris Trust transaction on February 9th, receiving $4 billion in cash from the spin-off of its Biosciences & Diagnostics Solutions business.
  • BDX reported revenue of $4.7 billion for the second quarter of fiscal 2026, marking a 2.6% year-over-year increase on a FXN basis.
  • Shares gained 9.42% over the past 52 weeks, demonstrating strong momentum despite recent market volatility.
  • The company's diversified product portfolio is used by hospitals, doctors, and the pharmaceutical industry, with 90% of hospital patients encountering at least one of BD's more than 45 billion medical products annually.
  • Hedge fund interest in BDX increased, with 48 portfolios holding the stock at the end of Q1 2026, up from 45 in the previous quarter.
Risk Factors
  • Becton, Dickinson and Company (BDX) is not included on Hinde Group's list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026, indicating a lack of top-tier institutional confidence.
  • The firm explicitly states that while acknowledging BDX's potential, they believe certain AI stocks offer greater upside potential and carry less downside risk, suggesting BDX is viewed as inferior in the current market environment.
  • Hinde Group initiated its position in BDX in July 2025 as a 'special situation investment,' implying it is not a core long-term holding but rather a tactical play with specific risks.
  • The company recently completed a Reverse Morris Trust transaction on February 9th, spinning off its Biosciences & Diagnostics Solutions business to Waters Corporation, which may signal strategic contraction or restructuring concerns.
  • Despite a recent 52-week gain of 9.42%, BDX's one-month return was negative at -0.60%, showing recent downward price momentum.
  • The article promotes alternative investments in AI stocks that benefit from Trump-era tariffs and onshoring trends, positioning them as superior alternatives to BDX for investors seeking undervalued opportunities.
Full Analysis
Hinde Group, an investment management firm, highlighted Becton, Dickinson and Company (NYSE:BDX) in its first-quarter 2026 investor letter as a special situation investment initiated in July 2025. The portfolio delivered a gross return of 3.80% and a net return of 3.41% for the quarter, outperforming the S&P 500 Index which returned -4.33%. Becton Dickinson is described as a leading medical technology company that develops, manufactures, and sells a diversified range of medical supplies, devices, laboratory equipment, and diagnostic products used by hospitals, doctors, the pharmaceutical industry, and individuals. Approximately 90% of hospital patients encounter at least one of the more than 45 billion medical products BD manufactures annually. On February 9th, Becton Dickinson completed its Reverse Morris Trust transaction with Waters Corporation, spinning off its Biosciences & Diagnostics Solutions business which merged with Waters Corporation. As consideration, BD received $4 billion in cash and shareholders received 0.135 shares of Waters Corporation common stock for each share of BDX held. Roughly 60% of Becton Dickinson's $18.5 billion revenue comes from the U.S., with around a quarter coming from Europe. The company closed at $148.41 per share on May 28, 2026, with a market capitalization of $40.89 billion and a one-month return of -0.60%, while shares gained 9.42% over the past 52 weeks. Hinde Group noted that Becton Dickinson reported revenue of $4.7 billion in the second quarter of fiscal 2026, marking an increase of 2.6% year-over-year on a FXN basis. While acknowledging the potential of BDX as an investment, Hinde Group stated they believe certain AI stocks offer greater upside potential and carry less downside risk. At the end of the first quarter, 48 hedge fund portfolios held Becton Dickinson, up from 45 in the previous quarter, though it is not on their list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026.